Kaken 1H FY18 (YE Mar'19) Results - First Glance
Key highlights NHI pricing pressure continues to take its toll on Kaken’s flagship drug, Artz (down 16% to ¥12.4b, ~30% of FY17 sales), driving...
406 Views
Japan: Treasury Share 'Kings' and 'Paupers'
TREASURY SHARES IN JAPAN - As a prelude to an upcoming insight on share buybacks in Japan, this note is a fork of Douglas Kim 's quick note on...
367 Views
Negative Impact of Price Cuts to Continue; New Opportunities Offer Marginal Benefit
We reiterate our “Equal-weight” rating on the stock after reviewing our model post 1Q FY18 (YE Mar-19) earningsLong Listed product sales under NHI...
325 Views
Japan Pharma - Drug Price Revision in April 2018
Japan, after the US and China, is the world’s third largest pharma industry, worth ~$70b in 2016. However, according to research and consulting...
246 Views
Kaken Pharmaceutical Co (4521:Tokyo): A Top-Class Pharmaceutical Company at a Discount to Fair Value
Share could have potential 77% upside. Using enterprise DCF method, our fair value estimate for the common stock is Yen 11,073. Shares of Kaken...
378 Views